Fatty Acid Esterification as a NASH Therapeutic Target
- PMID: 37984466
- PMCID: PMC10829519
- DOI: 10.1016/j.jcmgh.2023.10.011
Fatty Acid Esterification as a NASH Therapeutic Target
Comment on
-
GPAT1 Deficiency in Mice Modulates NASH Progression in a Model-Dependent Manner.Cell Mol Gastroenterol Hepatol. 2024;17(2):279-291. doi: 10.1016/j.jcmgh.2023.10.002. Epub 2023 Oct 14. Cell Mol Gastroenterol Hepatol. 2024. PMID: 37844795 Free PMC article.
References
-
- Wong R.J., Aguilar M., Cheung R., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555. - PubMed
-
- Le M.H., Le D.M., Baez T.C., et al. Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023;79:287–295. - PubMed
-
- Neschen S., Morino K., Hammond L.E., et al. Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell Metab. 2005;2:55–65. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical